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BACKGROUND: We have recently demonstrated that expression profiling is a more accurate and objective method to classify gliomas
than histology. Similar to most expression profiling studies, our experiments were performed using fresh frozen (FF) glioma samples
whereas most archival samples are fixed in formalin and embedded in paraffin (FFPE). Identification of the same, expression-based
intrinsic subtypes in FFPE-stored samples would enable validation of the prognostic value of these subtypes on these archival samples.
In this study, we have therefore determined whether the intrinsic subtypes identified using FF material can be reproduced in FFPE-
stored samples.
METHODS: We have performed expression profiling on 55 paired FF-FFPE glioma samples using HU133 plus 2.0 arrays (FF) and Exon
1.0 ST arrays (FFPE). The median time in paraffin of the FFPE samples was 14.1 years (range 6.6–26.4 years).
RESULTS: In general, the correlation between FF and FFPE expression in a single sample was poor. We then selected the most variable
probe sets per gene (n¼ 17 583), and of these, the 5000 most variable probe sets on FFPE expression profiles. This unsupervised
selection resulted in a better concordance (R2¼ 0.54) between expression of FF and FFPE samples. Importantly, this probe set
selection resulted in a correct assignment of 87% of FFPE samples into one of seven intrinsic subtypes identified using FF samples.
Assignment to the same molecular cluster as the paired FF tissue was not correlated to time in paraffin.
CONCLUSION: We are the first to examine a large cohort of paired FF and FFPE samples. We show that expression data from FFPE
material can be used to assign samples to intrinsic molecular subtypes identified using FF material. This assignment allows the use of
archival material, including material derived from large-randomised clinical trials, to determine the predictive and/or prognostic value
of ‘intrinsic glioma subtypes’ on Exon arrays. This would enable clinicians to provide patients with an objective and accurate diagnosis
and prognosis, and a personalised treatment strategy.
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The classification of tumour subtypes influences treatment
decisions for many types of cancer. Accuracy in classifying cancer
subtypes is therefore necessary to provide patients with correct
diagnosis, prognosis and an optimal treatment strategy. As
histological classification is often difficult in poorly differentiated
tumours, this classification method urgently needs improvement.
Gene expression profiling of cancer offers an accurate and
objective method for classifying cancer subtypes (Sorlie et al,
2001; Valk et al, 2004). For example, in gliomas, the most common
primary brain tumour in adults, gene expression profiling has
identified distinct intrinsic subtypes of gliomas (Nutt et al, 2003;
Freije et al, 2004; Phillips et al, 2006; Louis et al, 2007; Shirahata
et al, 2007, 2009; Gravendeel et al, 2009; Li et al, 2009; Madhavan
et al, 2009; Verhaak et al, 2010). We have performed unsupervised
gene expression profiling in a cohort of 276 gliomas of all
histological subtypes (Gravendeel et al, 2009). In this largest
single-institution study conducted to date, we identified seven
molecular glioma clusters. The molecular clusters were signifi-
cantly better predictor of survival than histology, and were
characterised by specific genetic changes. Data were validated
and confirmed on six large external data sets. When validated in
prospective studies these molecular clusters could contribute to
clinical decision making. However, this study was conducted using
RNA isolated from fresh frozen (FF) tissue. Unfortunately, FF
tissue is scarce; most of the tissue archives with matched clinical
outcome data are fixed in formalin and embedded in paraffin
(FFPE). RNA isolated from FFPE material is often degraded and
chemically modified as a result of the archiving method (Masuda
et al, 1999; Farragher et al, 2008). However, new techniques have
shown promising results in genome-wide expression profiling of
RNA isolated from FFPE (Hoshida et al, 2008; Linton et al, 2008,
2009; Hall et al, 2011; Mittempergher et al, 2011).
Techniques used to study gene expression with FFPE material
thus far have mostly been limited to single-gene analysis with
RT–qPCR. Such techniques have demonstrated to be clinically
relevant on a limited set of ‘classifier’ genes (Ma et al, 2006; Colman
et al, 2010). Other multiplex assays (DASL, Quantigene, Nanostring,
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Fluidigm) have also shown promising results using distinct
classifier genes (Canales et al, 2006; Geiss et al, 2008; Hoshida
et al, 2008; Linton et al, 2008, 2009; Spurgeon et al, 2008; Hall et al,
2011; Mittempergher et al, 2011). Although whole-genome
approaches for degraded RNA samples have improved over the
last few years, the performance of current techniques to detect
more subtle differences between cancer subtypes remains to be
confirmed.
In this study, we therefore have performed expression analysis
using a large cohort paired FF-FFPE glioma tissue using Exon 1.0
ST ‘exon’ arrays (Affymetrix, Santa Clara, CA, USA). Expression
profiling using such a cohort has thus far not been performed.
Most expression profiling studies using FF tissues have been
performed on HU133-type arrays (A, AþB or the þ 2.0 version),
whereas best results using FFPE samples have been obtained using
the Exon 1.0 ST arrays. In this study, we therefore compare the
expression of FF samples on HU133 plus 2.0 arrays with FFPE
samples on Exon 1.0 ST arrays. Previous studies have demon-
strated good overall correlation of HU133 Plus 2.0 with Exon 1.0
ST arrays (Okoniewski et al, 2007). We show that expression data
from FFPE glioma material is concordant with expression data
from matched FF tissue, and can be used for molecular profiling in
gliomas. Furthermore, this molecular profiling is able to identify
the subtle differences between the molecular glioma subtypes.
PATIENTS AND METHODS
Patient samples
We selected 55 paired FF-FFPE samples from the Erasmus
University Medical Center glioma tumour archive. The FF and
the FFPE samples were taken simultaneously from the tumour as
parallel biopsies. All samples were visually inspected at the time of
this study for the tumour content by the neuropathologist so that
samples containing at least 80% of tumour tissue were selected.
The FF samples selected were used in a previous study in which
seven molecular clusters were identified (Gravendeel et al, 2009).
The selection contained B10 samples from each molecular
cluster. FF expression profiling results were reported previously
(Gravendeel et al, 2009). The RNA from the FF tissue was extracted
and hybridised in 2008. The RNA from the FFPE tissue was
extracted and hybridised in 2010. Clinical and molecular data from
the glioma samples included were reported previously (Gravendeel
et al, 2009). The use of patient material was approved by the
Institutional Review Board of the ErasmusMC, Rotterdam, the
Netherlands (nr MEC 221.520/2002/262; date of approval 22 July
2003, and MEC-2005-057, date of approval 14 February 2005). For
this use, patients gave written informed consent according to the
Institutional and National guidelines. The fixation method of
tissue in the Erasmus MC did not change over the last 25 years.
RNA from FFPE extraction
Five sections of 10 mm thick were cut from each tissue block. The
High Pure RNA Paraffin Kit (Roche Applied Science, Mannheim,
Germany) was used to isolate the RNA from the paraffin. After
isolation the RNA was purified by ethanol precipitation (Supple-
mentary Table 1). The quantity and integrity of the RNA was
measured using a Nanodrop, and an Agilent 2100 BioAnalyzer
RNA 6000 Nano Assay (Agilent Technologies, Amstelveen, the
Netherlands). After total RNA isolation and purification, samples
were diluted to 50 ngml1 and stored at 801C until use.
qPCR
We randomly selected 11 samples that were assigned to two
molecular clusters based on the FF expression data (Cluster 9
(n¼ 5) and Cluster 18 (n¼ 6); Gravendeel et al, 2009). Four genes
(two upregulated, two downregulated) that discriminate between
the two subtypes were examined for differential gene expression
(EMP3, SLC2A10, SUSD5 and CSMD3). These genes were
identified using a t-test in combination with fold change. ACTB,
GAPDH were used as control. All reactions were performed in
duplicate. Primers and conditions are described in Supplementary
Table 2.
Arrays
A total of 150 ng per sample of the extracted RNA (FFPE) was used
for the Exon 1.0 ST arrays (Affymetrix). Sample labelling and array
hybridisation were performed by AROS Applied Biotechnology AS
(Arhus, Denmark) according to the standard Affymetrix protocols
in combination with Nugen WT-Ovation technology (FFPE V2 and
Exon modules; San Carlos, CA, USA; n¼ 55). Expression arrays
(HU 133 plus 2.0 (Affymetrix) using FF material was reported
previously (Gravendeel et al, 2009).
Quantile normalised robust multichip average (RMA) expres-
sion levels of 22 011 genes and 287 329 exons were extracted from
Affymetrix Exon 1.0 ST arrays using Expression Console
(Affymetrix). ClusterRepro (an R package) was used to assign a
sample to a defined molecular subtype (Kapp and Tibshirani,
2007).
Statistics
Differences between Kaplan–Meier survival curves were calculated
by the log-rank (Mantel–Cox) test. Differences in age and RIN-
scores of the tissue blocks were calculated using a t-test and a
Mann–Whitney test. Significance of correlation coefficients was
calculated using the P-value calculator for correlation coefficients
(http://www.danielsoper.com/statcalc3).
RESULTS
Sample characteristics
At total of 55 FFPE samples were included in the study. These
samples included 29 glioblastomas, 5 astrocytomas grade III,
5 as grade II, 4 mixed oligoastrocytoma grade III (OA II), 2 OAs
grade II, 8 oligodendrogliomas grade III and 2 pilocytic astrocytoma.
The median time in paraffin of the FFPE samples was 14.1 years
(range 6.6–26.4 years). The median RIN score of the RNA was 2.4
(range 1.1–2.7). Sample characteristics are listed in Table 1.
qPCR
We first aimed to determine whether differences identified using
expression profiling on snap frozen tissue could be found on RNA
isolated from FFPE samples. For this initial test, we selected for
samples that were assigned to two distinct molecular clusters based
on the FF expression data (Cluster 9 (n¼ 5) and Cluster 18 (n¼ 6);
Gravendeel et al, 2009). Cluster 9 shows a favourable prognosis
compared with the other clusters, and is specific for loss of
heterozygosity of 1p and 19q, as well as a high frequency of IDH1
mutations. Cluster 18 has poor prognosis and is characterised by
EGFR amplifications and CDKN2A deletions. The RT–qPCR
results showed that both direction and fold change of all four
genes in all samples could be recapitulated on RNA isolated from
FFPE samples. The overall correlation was relatively strong
r2¼ 0.61 (Po0.001). Correlations (r2) and P-values for individual
genes EMP3, SUSD5, CSMD3 and SLC2A10 were 0.34 (P¼ 0.024),
0.840 (Po0.001), 0.849 (Po0.001) and 0.255 (P¼ 0.047), respec-
tively. These results demonstrate that differences in gene expres-
sion are retained in RNA isolated from FFPE samples (Figure 1).
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Exon array expression data and molecular clustering
analysis
After the hybridisation of the exon 1.0 ST arrays, we compared the
RMA normalised expression data of the exon arrays (FFPE) with
exon 1.0 ST arrays that were analysed in earlier studies (FF tissue;
French et al, 2007; Schutte et al, 2008). The exon arrays with FF
tissue showed expression of more probe sets, as well as higher
expression levels than the exon arrays with FFPE material
(Supplementary Figure 2). On Hu133 plus 2.0 arrays (using FF
samples), 9261±117 (52.9%) probe sets are expressed at RMA
levels46.5. On exon arrays, 59 618±20 337 (20.7%) probe sets are
detected at Po0.01, using DABG values. It should be noted that
significantly more probe sets are detected on exon arrays using FF
Table 1 Patient and sample characteristics
Db
no
Survival
(years) Status
PA
diagnosis
Age FFPE
material
(years)
RIN
score
Correlation
(r2) FF and
FFPE
P-value
correlation FF
and FFPE
8 9.82 Dead OD III 15.3 1.90 0.24 o0.001
40 10.28 Dead OD III 18.9 2.20 0.29 o0.001
55 17.49 Dead OD III 23.9 2.30 0.30 o0.001
63 3.28 Dead GBM 9.9 2.40 0.12 o0.001
77 1.30 Dead GBM 12.2 2.60 0.03 0.02
92 1.26 Dead GBM 11.3 1.10 0.20 o0.001
98 0.98 Dead GBM 12.1 2.30 0.13 o0.001
99 0.86 Dead GBM 13.3 N/A 0.03 0.024
104 0.21 Dead GBM 10.4 N/A 0.15 0.024
105 1.03 Dead GBM 16.0 N/A 0.08 o0.001
112 0.59 Dead GBM 16.0 N/A 0.10 o0.001
119 0.18 Dead GBM 13.1 2.30 0.15 o0.001
123 2.05 Dead GBM 13.9 2.50 0.15 o0.001
130 6.31 Dead GBM 15.1 1.40 0.08 o0.001
134 1.48 Dead A II 13.9 N/A 0.06 o0.001
143 4.79 Dead A II 13.4 2.70 0.10 o0.001
174 0.28 Dead GBM 19.3 N/A 0.05 o0.001
183 0.12 Dead GBM 12.3 N/A 0.14 o0.001
194 0.19 Dead A III 20.8 1.90 0.13 o0.001
198 6.27 Dead A III 21.8 2.40 0.11 o0.001
199 1.11 Dead GBM 20.2 2.10 0.14 o0.001
206 0.29 Dead GBM 11.7 2.50 0.03 0.028
209 1.96 Dead OA III 11.0 2.50 0.09 o0.001
227 3.10 Lost to follow-up GBM 10.9 N/A 0.01 0.22
253 0.62 Dead GBM 9.3 2.20 0.32 o0.001
256 0.27 Dead GBM 14.1 2.40 0.15 o0.001
257 3.30 Dead OD III 17.9 2.50 0.23 o0.001
258 2.26 Dead GBM 18.4 2.50 0.12 o0.001
259 5.02 Dead OD III 13.5 2.40 0.02 0.087
286 5.56 Lost to follow-up GBM 24.6 2.30 0.13 o0.001
291 0.63 Dead OA III 20.3 2.10 0.24 o0.001
293 2.99 Dead OD III 22.7 2.50 0.10 o0.001
315 0.61 Dead GBM 15.4 N/A 0.14 o0.001
336 1.19 Dead A II 11.9 2.40 0.15 o0.001
353 9.79 Dead GBM 26.0 2.10 0.10 o0.001
380 1.61 Dead GBM 7.5 2.20 0.04 0.002
387 3.32 Dead GBM 17.0 N/A 0.12 o0.001
393 0.06 Dead GBM 14.2 2.10 0.17 o0.001
416 15.82 Dead OD III 26.4 2.50 0.14 o0.001
420 1.32 Dead A II 17.4 N/A 0.06 o0.001
441 3.76 Dead OA II 18.9 2.50 0.02 0.06
445 1.18 Dead OA III 18.9 2.20 0.25 o0.001
446 0.45 Dead A III 8.9 1.60 0.04 o0.001
467 0.05 Dead A III 10.9 2.50 0.01 0.15
473 1.20 Dead A III 22.7 2.50 0.20 o0.001
515 0.35 Dead GBM 7.4 2.50 0.00 0.45
536 6.39 Alive OA II 6.6 2.40 0.13 o0.001
565 2.79 Dead GBM 14.2 1.90 0.23 o0.001
566 0.48 Dead GBM 13.8 N/A 0.18 o0.001
568 16.31 Alive OA III 16.5 2.60 0.20 o0.001
619 0.48 Dead OD III 11.9 2.50 0.28 o0.001
628 7.52 Dead A II 10.9 N/A 0.21 o0.001
629 2.22 Dead GBM 10.8 2.50 0.08 o0.001
711 14.18 Alive PA 14.3 1.30 0.10 o0.001
712 0.19 Lost to follow-up PA 13.9 2.60 0.17 o0.001
Abbreviations: A III¼ astrocytoma grade III; A II¼ astrocytoma grade II; Db¼ database number; FF¼ fresh frozen; FFPE¼ fixed in formalin and embedded in paraffin;
GBM¼ glioblastoma; OA II¼ oligoastrocytoma grade II; OA III¼ oligoastrocytoma grade III; OD II; oligodendroglioma grade II; OD III¼ oligodendroglioma grade III; RIN¼RNA
integrity number.
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tissue (141 493±12 924 (49.2%), see also Supplementary Figure 1).
In addition, the distribution of the RMA expression histograms of
the FFPE glioma tissue is shifted compared with the expression
histograms of exon arrays with FF tissue (Supplementary Figure 3).
Correlation expression FF vs FFPE
Exon arrays contain one or more probe sets per exon for each gene
(287 329 core probe sets for 22 011 genes), whereas only one data
point per gene is generated on HU133plus2 arrays (17 583 genes,
when using the alternative .cdf based on entrezgene; Dai et al,
2005). We therefore first selected the probe sets on exon arrays
that likely contain most of the biological information. Because
genes that discriminate between molecular subtypes are by
definition differentially expressed, and thus show a relatively high
variance in expression, we selected the probe set with highest
variance per gene (n¼ 17 583 probe sets (6.2% of all ‘core’ probe
sets); log2 normalised data). Selecting the most variable probe set
on exon arrays does not always identify those with highest
correlation to expression on HU133plus2.0 arrays. However,
selection based on variance approaches both data sets
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Figure 1 Correlation of the expression of the RNA (FFPE) and the RNA (FF) of 11 matched FF-FFPE samples. The four genes (EMP3, SLC2A10, SUSD5,
CSMD3) chosen are the most discriminating genes between two very distinct molecular subtypes. (A) The correlation between the DCt of the qPCR results
(FFPE material) and the expression data of the HU133plus 2.0 arrays (FF tissue). A high DCt value is indicative for a low expression value. The correlation
plot shows a good correlation between the FF expression and the FFPE expression. (B) This correlation view shows the correlation of the expression of the
FF tissue (HU133 plus 2.0 array) and the expression of the FFPE tissue (qPCR). The green color represents low expression, red represents high expression.
The molecular clusters can be identified using the RNA isolated from FFPE. The color reproduction of this figure is available at the British Journal of Cancer
online.
Molecular clustering
Fresh frozen tissue
(HU133A plus 2.0)
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Figure 2 Flow charts of the selection of probe sets containing the most informative gene expression data. (A) We first selected the probe set with
highest variance per gene (n¼ 17 583 probe sets; FFPE: 17 583). In our previous study, we performed molecular clustering with FF tissue based on the 5000
most variable genes (FF: 5000). The overlap between the most variable probe sets in FF tissue and the most variable probe sets in FFPE tissue (FF: 5000/
FFPE: 17 853) consisted of 4620 matching probe sets. On the basis of these 4620 probe sets, samples were assigned to one of the seven molecular clusters
using ClusterRepro. (B) When using exon arrays, it is possible that no informative probe sets are available for a single gene, and such probe sets may be
filtered out by selecting not only the most variable probe set per gene, but also, of these, the most variable 5000 probe sets (FF: 5000/FFPE: 5000). By using
this filter, there are 1827 overlapping probe sets. ClusterRepro was used to assign the samples to one of the seven molecular clusters based upon these
overlapping probe sets.
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independently and avoids potential circular arguments. All further
analysis was therefore done using the selection of exon array probe
sets based on variance as starting data set.
In our previous study, we performed molecular clustering with
FF tissue based on the 5000 most variable genes (FF: 5000). The
overlap between the most variable probe sets in FF tissue and the
most variable probe sets in FFPE tissue (FF: 5000/FFPE: 17 853)
consisted of 4620 matching probe sets (Figure 2A).
The set of 17 853 probe sets assumes that all genes have at least
one informative probe set per gene. It is however possible all probe
sets that belong to the same gene perform poorly. We therefore
also performed a further selection of the 17 583 exon array probe
sets, by selecting the 5000 most variable probe sets of these 17 583
(1.74% of the total number of ‘core’ probe sets, Figure 2B). Using
the 5000 most variable probe sets for both FF and FFPE material
showed an overlap of 1827 matching probe sets (FF: 5000/FFPE:
5000, 1827 overlapping probe sets; Figure 2B).
We first compared the gene expression data (FF) of the genes used
in the qPCR analysis (EMP3, SUSD5, CSMD3 and SLC2A10) with the
expression data of the FFPE material. For this analysis we used the
expression data of the same 11 samples that were also used in the
qPCR analysis. Figure 3 shows the correlation of the qPCR genes
(EMP3, CSMD3 and SLC2A10) between the expression of the FF
RNA and the FFPE RNA. These results show a weak correlation
between the FF and FFPE expressions for both EMP3 and SLC2A10
(r2¼ 0.32; P¼ 0.028 and r2¼ 0.21; P¼ 0.067), and a good correlation
for CSMD3 (r2¼ 0.97; Po0.001). There were no data available of
SUSD5 as there were no probe sets of this gene on exon 1.0 ST arrays.
These results highlight that exon arrays can show a concordance in
gene expression compared with FF tissue, but that a selection of the
biologically most informative probe sets is required.
We next compared the normalised expression data of the 5000
most variable genes as used in our previous study, with the
expression of the most variable exons (FF: 5000/FFPE: 17 583, 4620
matching probe sets; Gravendeel et al, 2009). In general, the
strength of correlation between FF and FFPE expression in a single
sample (sample 8) was weak (r2¼ 0.24, Po0.001). It should be
noted that part of the between FF and FFPE sample variability is
biological: The snap frozen and FFPE tissues are not taken from
exactly the same location within a tumour. For this analysis we
compared differential gene expression between samples of cluster
9 and 18 (separately for FF and FFPE). The correlation (r2) in
differential gene expression between FF and FFPE was 0.38.
We did the same analysis for the most variable 5000 probe sets
(FF: 5000/FFPE: 5000, 1827 overlapping probe sets). Differential
gene expression between samples of Cluster 9 and Cluster 18 then
showed a relatively strong correlation between FF on HU133 plus
2.0 and FFPE on HuEx 1.0 ST arrays (R2¼ 0.54; Po0.001 (Figure 4).
Our results demonstrate that differential gene expression between
samples observed using RNA isolated from FF tissue is at least
partially retained on RNA isolated from FFPE samples.
Expression data of the FF samples is performed HU133 Plus 2.0
arrays, a platform that is different from the platform used for the
FFPE samples (HuEx 1.0 st arrays). We have therefore compared
expression of all probes (287 329) between FF and FFPE on exon
arrays of eight matched samples (8, 40, 130, 206, 257, 259, 275 and
293). In general, the correlation between FF and FFPE samples
on the same platform was reasonable (r2¼ 0.315±0.093 range
0.210–0.450, Po0.001). This correlation was much better than the
overall correlation (also using 287 329 probe sets) between FF
on HU133 Plus 2.0 arrays and FFPE on HuEx 1.0 st arrays
(0.034±0.023). The better correlation between FF and FFPE
samples on the same platform therefore indicates that differential
gene expression is better retained when using the same platform.
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Figure 3 Correlation of the qPCR genes (EMP3, CSMD3 and SLC2A10) between the expression of the FF RNA and the FFPE RNA. We compared the
gene expression data (FF; HU133 plus 2.0) of the four genes used in the qPCR analysis (EMP3, SUSD5, CSMD3 and SLC2A10) with the expression data of
the FFPE material (Exon 1.0 ST). We used the expression data of the same 11 samples that were also used in the qPCR analysis. (A) and (B) show a weak
correlation for both EMP3 (r2¼ 0.32) SLC2A10 (r2¼ 0.21). A good correlation is seen for CSMD3 (r2¼ 0.97) (C). There were no data available of SUSD5
as there were no probe sets of this gene on exon 1.0 ST arrays.
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Figure 4 Differential gene expression between samples of Cluster 9 and
18. The differential gene expression between samples of two molecularly
very distinct clusters (Cluster 9 and 18) showed a relatively good correlation
between 18 FF samples on HU133 plus 2.0 and 18 FFPE samples on HuEx
1.0 ST arrays (R2¼ 0.54). For this analysis we used the 5000 most variable
probe sets of the exon expression data and subtracted the median
expression of Cluster 18 from the median expression of Cluster 9.
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Cluster assignment
Recently, we described the identification of seven molecular
glioma subtypes based on gene expression profiling, which are
better predictors of survival than histology (Gravendeel et al,
2009). Our final assessment to determine the suitability of RNA
isolated from the FFPE samples was to confirm sample assignment
to individual molecular subtypes. Clustering results are repre-
sented in Table 2. Overall, assignment to the correct cluster (e.g.,
assignment to the same molecular cluster as the FF tissue in the
previous study) was seen in 76% (n¼ 42) of the samples (FF: 5000/
FFPE: 17 583). However, part of the variability between FF and
FFPE samples is biological and may represent tumour hetero-
geneity. This heterogeneity is specifically notable for assignment to
Cluster 0, as assignment to this cluster depends on the relative
amount of non-neoplastic tissue present. Indeed, the overlap
between FF and FFPE cluster assignment when excluding samples
that are assigned to Cluster 0 is 86% (n¼ 42/49). A total of 13
samples were assigned to a different molecular cluster, 7 without
Cluster 0.
Similar performance in cluster assignment was observed when
using the 5000 most variable exon probe sets (FF: 5000/FFPE: 5000;
Figure 2B). Assignment to the identical cluster was seen in 75%
(n¼ 41) of the samples, 87% without Cluster 0 (n¼ 41/47).
Assignment to the same molecular cluster as the paired FF tissue
did not have a significant correlation with the time in paraffin. The
‘wrongly’ assigned blocks even showed a slightly shorter median
time in paraffin than the ‘correctly’ assigned samples (11.9 vs 14.3
years; P¼ 0.07). The average RIN score of the incorrectly assigned
samples was 2.18±0.40, and was not significantly different from the
RIN scores of the correctly assigned samples 2.24±0.34, P¼ 0.71).
The high degree of overlap between FF and FFPE sample
assignment (both FF: 5000/FFPE: 17 583 and FF: 5000/FFPE: 5000)
is reflected in a highly similar patient survival curves (Figure 5).
However, FFPE survival curves also include three samples that
originally were assigned to Cluster 0.
DISCUSSION
In this study, we describe a method that allows analysis of gene
expression profiling of FFPE cancer tissue using HuEx 1.0 ST arrays.
Our data show that expression data of RNA isolated from FFPE and
FF tissues are comparable. However, a selection on the most
informative probe sets (based on highest variance for each probe
set/gene and highest variance between genes) is required. RIN score
and the age of the FFPE tissue blocks do not influence the gene
expression results. The average RIN score and the average time in
paraffin of the incorrectly assigned samples were not significantly
different from the RIN scores and time in paraffin of the correctly
assigned samples. The probe sets identified in this study can be used
in other profiling studies that lack paired FF samples.
Differential gene expression between samples is well retained
(Figure 4). This is also illustrated by the identical assignment to
intrinsic molecular subtypes for both FF and FFPE glioma tissue in
up to 87% of the samples (Table 2). It should be noted that FF and
FFPE tissues are resected from different parts of the tumour.
Therefore, tumour heterogeneity may also contribute to the
differential assignment between FF and FFPE samples.
Previous studies demonstrated that FFPE samples can be used for
gene expression profiling either using the Affymetrix (Exon 1.0 and
HU133 plus 2.0) or using the Illumina (DASL) platforms (Hoshida
et al, 2008; Linton et al, 2008, 2009; Hall et al, 2011; Mittempergher
et al, 2011). However, these studies had limited sample size, lacked
controlled experiments with paired FF-FFPE sample analysis or
were used to differentiate between very distinct cancers. Our study
is the first to use a large cohort of paired FF-FFPE glioma samples
for expression profiling with exon 1.0 ST arrays. We show that
degraded RNA that is up to 25 years old, is suitable to identify subtle
differences between subtypes within one specific cancer.
Other genome-wide techniques are also available that can
perform expression profiling on FFPE samples, including the
DASL platform (Illumina). The platform chosen for this study was
based on reports from literature (Linton et al, 2008, 2009), and it is
beyond the scope of this manuscript to compare performance of
both platforms. Although it is possible other platforms perform
better on FFPE samples, our study demonstrates that sufficient
Table 2 Cluster assignment of samples
Db
no
Clustering
RNA (FF)
Clustering
RNA FFPE
17853 most
variable exons
Clustering
RNA FFPE
5000 most
variable exons
8 9 9 9
40 9 9 9
55 9 9 9
63 0 17 0
77 0 23 23
92 18 18 18
98 22 22 22
99 23 17 0
104 23 23 23
105 23 23 23
112 23 23 23
119 22 22 22
123 17 17 17
130 9 9 9
134 17 17 17
143 0 0 0
174 23 23 23
183 23 23 23
194 18 18 18
198 17 17 17
199 18 18 18
206 22 0 0
209 17 17 17
227 22 17 17
253 18 18 18
256 18 18 18
257 9 9 9
258 18 23 23
259 9 23 23
286 17 17 17
291 18 18 18
293 0 9 9
315 17 17 17
336 22 9 0
353 22 22 22
380 9 23 23
387 22 22 17
393 23 23 23
416 17 17 17
420 22 0 0
441 9 0 0
445 18 18 18
446 16 23 23
467 22 22 22
473 9 9 9
515 23 23 23
536 17 17 17
565 23 23 23
566 23 23 23
568 17 17 17
619 18 18 18
628 0 0 0
629 23 23 23
711 16 16 0
712 16 16 16
Abbreviations: FF¼ fresh frozen; FFPE¼ fixed in formalin and embedded in paraffin.
Glioma profiling using FFPE material
LAM Gravendeel et al
543
British Journal of Cancer (2012) 106(3), 538 – 545& 2012 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
information is stored in FFPE samples so that it can be used for
expression profiling using exon 1.0 ST arrays. Our method allows
molecular classification of archived clinical trial samples to
evaluate the predictive and prognostic values of the molecular
glioma clusters. Furthermore, it allows assignment of FFPE
material of newly diagnosed patients to molecular clusters. Such
assignment would allow clinicians to improve patients’ diagnosis
and would contribute to treatment decisions.
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Figure 5 Kaplan–Meier survival curves of the seven molecular clusters identified in FF and FFPE material show a high resemblance. (A) shows the survival
of the seven molecular clusters identified, using FF material of the 55 patients included in this study (HU133 plus 2.0 arrays). (B) shows the survival curves of
the molecular clusters to which the FFPE tissue was assigned based on the 17 852 most variable probe sets from the Exon 1.0 ST arrays. (C) Shows the
survival curves of the molecular clusters to which the FFPE tissue was assigned by filtering the exon data on the 5000 most variable probe sets.
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